April 2020 - RI Bio

ProThera Biologics and Takeda Enter Global Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)

Apr 24, 2020 | International, Local, National, Regional

Providence, R.I., and Osaka, JAPAN, April 23, 2020 – ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited [TSE:4502/NYSE:TAK] (“Takeda”) today announced that they have entered into a global licensing agreement to develop a novel plasma-derived...

Diagnostic Robotics from Israel Announces Partnership with the State of Rhode Island to Launch an AI Platform for Remote Assessment and Monitoring of COVID-19

Apr 24, 2020 | Uncategorized

“We are incredibly excited about the partnership with Diagnostic Robotics, Diagnostic Robotics is a leader in using innovative technology to ensure people get the right care at the right time – including during the COVID-19 pandemic. By making it easier for people to...

Join RI Bio in the Fight Against COVID-19

Apr 16, 2020 | Uncategorized

How Can You Help? Calling on all Life Sciences entrepreneurs, companies and organizations to help us fight COVID-19 in Rhode Island. We’re reaching out to see how we can best support you and welcome your ideas and thoughts on how best to keep our community...

PROJO Editorial—My Turn: Patrice Milos, RI Bio Board: Massive testing can help reopen economy

Apr 7, 2020 | Local

In the face of today’s global health pandemic, we are experiencing a time of tremendous uncertainty. As the former CEO of a molecular diagnostic laboratory in Cambridge, Massachusetts, I believe advanced diagnostic technologies are ready to address the challenges we...

FCC Chair Proposes $200 Million COVID-19 Telehealth Grant Program

Apr 1, 2020 | National

March 31, 2020 3:44AM ET (Inside Health Policy) The Federal Communications Commission Chair Ajit Pai on Monday (March 30) proposed using $200 million allocated by Congress for a grant program for hospitals and health system providers aiming to use telehealth in their...